Skip to main content
Equibles
LCTX logo

LCTX · Lineage Cell Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track LCTX — free

Use LCTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LCTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.93 0.00 (-0.31%) At close · Oct 5
Russell 2000 member Rebalance outlook locked
Customer concentration — top 2 customers 92% of revenue

2 customers — 92% of revenue (the year ended December 31, 2025)

“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”

One customer — 92% of revenue (the year ended December 31, 2024)

“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
View the 10-K filed Mar 5, 2026
Market Cap
$260.49M
Shares
252.91M
Volume · Oct 5 1.39M Avg daily vol (3M) 1.14M

Lineage Cell Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Lineage Cell Therapeutics, Inc. (LCTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲32.1% $3.00M −$6.07M '22 Q3 22-11-10 ▲64% $1.92M −$6.35M '22 Q4 23-03-09 ▼54.4% $2.39M −$4.37M '23 Q1 23-05-11 ▼29.2% $3.23M −$5.23M '23 Q2 23-08-10 ▼58.4% $1.25M −$7.11M '23 Q3 23-11-09 ▲9% $2.09M −$4.78M '23 Q4 24-03-07 ▼39.5% $1.44M −$6.54M '24 Q1 24-05-09 ▼56.3% $1.41M −$5.76M '24 Q2 24-08-08 ▲203.3% $3.78M −$3.03M '24 Q3 24-11-14 ▲37.4% $2.87M −$3.27M '24 Q4 25-03-10 ▲4% $1.50M −$4.14M '25 Q1 25-06-02 ▲96.4% $2.77M −$30.46M '25 Q2 25-08-12 ▼2.6% $3.68M −$29.78M '25 Q3 25-11-06 ▲130.4% $6.61M $851,000 '25 Q4 26-03-05 ▲14.8% $1.73M −$4.81M '26 Q1 26-05-12 LATEST ▼61.3% $1.07M $1.48M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
Positive tone OPC1 spinal cord injury program Clinical trial cadence and patient enrollment Regulatory and manufacturing risk commentary
Revenue
$1.07M
▼ 61.3% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Confident tone Pipeline diversification and platform leverage Manufacturing philosophy and process risk Clinical trial execution / site expansion
Revenue
$1.73M
▲ 14.8% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Positive tone Manufacturing Platform (Alloscope) Israel Operations and Employee Safety Pipeline Expansion Beyond Oncology
Revenue
$6.61M*
▲ 130.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript
Confident tone Partnership with Roche/Genentech Manufacturing and cost control Islet cell / Type 1 diabetes initiative
Revenue
$3.68M
▼ 2.6% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript
Positive tone Spinal cord injury (OPC1) clinical program Roche/Genentech partnership and Phase 2A trial Manufacturing and platform technology
Revenue
$2.77M
▲ 96.4% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-06-02
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript
Positive tone OpRegen Phase 2a GAlette Study OPC1 spinal cord injury dose study Surgical delivery optimization
Revenue
$1.50M
▲ 4% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call
Revenue
$2.87M*
▲ 37.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript
Confident tone OpRegen / Dry AMD program (partnered with Roche/Genentech) FDA interactions and OPC1 / DOSED study startup Pipeline expansion and hearing loss (ANP1) program
Revenue
$3.78M
▲ 203.3% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call
Revenue
$1.41M
▼ 56.3% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript
Confident tone OpRegen Phase I/IIa 24-month data Genentech/Roche partnership and services agreement Dry AMD commercial market
Revenue
$1.44M
▼ 39.5% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript
Confident tone OpRegen dry AMD program Roche/Genentech partnership OPC1 spinal cord program and IND clearance
Revenue
$2.09M
▲ 9% YoY
Diluted EPS
$-0.03
Gross margin
87.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2023 Earnings Call Transcript
Revenue
$1.25M
▼ 58.4% YoY
Diluted EPS
$-0.04
Gross margin
86.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2023 Earnings Call Transcript
Revenue
$3.23M
▼ 29.2% YoY
Diluted EPS
$-0.03
Gross margin
96.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2023 Earnings Call Transcript
Revenue
$2.39M
▼ 54.4% YoY
Diluted EPS
$-0.03
Gross margin
95.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2022 Earnings Call Transcript
Revenue
$1.92M
▲ 64% YoY
Diluted EPS
$-0.03
Gross margin
94.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2022 Earnings Call Transcript
Revenue
$3.00M
▲ 32.1% YoY
Diluted EPS
$-0.04
Gross margin
92.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2022 Earnings Call Transcript
Revenue
$4.55M
▲ 789.3% YoY
Diluted EPS
$-0.04
Gross margin
95.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2022 Earnings Call Transcript
Revenue
$5.24M
▲ 1239.4% YoY
Diluted EPS
$-0.04
Gross margin
96.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2021 Earnings Call Transcript
Revenue
$1.17M
▲ 229% YoY
Gross margin
82.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2021 Earnings Call Transcript
Revenue
$2.27M
▲ 297.5% YoY
Diluted EPS
$-0.05
Gross margin
56.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2021 Earnings Call Transcript
Revenue
$512,000
▲ 32.6% YoY
Diluted EPS
$-0.03
Gross margin
75.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2021 Earnings Call Transcript
Revenue
$391,000
▼ 23.9% YoY
Diluted EPS
$-0.01
Gross margin
71.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2020 Earnings Call Transcript
Revenue
$355,000
▼ 71.4% YoY
Gross margin
67.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2020 Earnings Call Transcript
Revenue
$571,000
▲ 0.7% YoY
Diluted EPS
$-0.05
Gross margin
82.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2020 Earnings Call Transcript
Revenue
$386,000
▼ 50.4% YoY
Diluted EPS
$-0.04
Gross margin
80.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2020 Earnings Call Transcript
Revenue
$514,000
▼ 44.6% YoY
Diluted EPS
$-0.06
▼ 120% YoY
Gross margin
81.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2019 Earnings Call
Revenue
$1.24M
▲ 63.7% YoY
Gross margin
90.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 876343 CUSIP 53566P109 13F (30d) 2 filings 2 filers Visit website Investor relations